Literature DB >> 18077020

Acute subarachnoid haemorrhage as a precipitant for takotsubo cardiomyopathy: a case report and discussion.

Moloy Das, Simon Gonsalves, Arin Saha, Stuart Ross, Gordon Williams.   

Abstract

Takotsubo cardiomyopathy is a recently recognised acute cardiac entity. It involves transient left ventricular apical ballooning, which is usually preceded by an episode of physiological or emotional stress. Its presentation may mimic acute myocardial infarction but there is no evidence of obstructive disease at coronary angiography. The aetiology of this condition has not been clearly defined, though a number of hypotheses have been put forward. Precipitating factors vary widely, including acute medical conditions and emotional stressors. We present a case of takotsubo cardiomyopathy precipitated by acute subarachnoid haemorrhage, the first report of this association in a Caucasian patient, and discuss the implications for clinicians involved in the management of such a case.

Entities:  

Mesh:

Year:  2008        PMID: 18077020     DOI: 10.1016/j.ijcard.2007.08.062

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Cerebral vasospasm and concurrent left ventricular outflow tract obstruction: requirement for modification of hyperdynamic therapy regimen.

Authors:  Gabriel Zada; Sergei Terterov; Jonathan Russin; Leonardo Clavijo; Steven Giannotta
Journal:  Neurocrit Care       Date:  2010-04       Impact factor: 3.210

Review 2.  Management of aneurysmal subarachnoid hemorrhage.

Authors:  Michael N Diringer
Journal:  Crit Care Med       Date:  2009-02       Impact factor: 7.598

3.  Stress-induced cardiomyopathy (Takotsubo)--broken heart and mind?

Authors:  Björn Redfors; Yangzhen Shao; Elmir Omerovic
Journal:  Vasc Health Risk Manag       Date:  2013-04-17

4.  The aetiology of myocardial injury after non-cardiac surgery.

Authors:  R B Grobben; W A van Klei; D E Grobbee; H M Nathoe
Journal:  Neth Heart J       Date:  2013-08-20       Impact factor: 2.380

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.